Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8568154 | 0.86 | L3MBTL1 (0.73) | L3MBTL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL12903055 | 0.85 | MEN1 (0.73) | L3MBTL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL7719697 | 0.82 | L3MBTL1 (0.63) | L3MBTL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL28164670 | 0.82 | L3MBTL1 (0.63) | L3MBTL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL28915977 | 0.82 | L3MBTL1 (0.68) | L3MBTL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL29727188 | 0.82 | L3MBTL1 (0.67) | L3MBTL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL1305492 | 0.82 | L3MBTL1 (0.67) | L3MBTL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL29727186 | 0.82 | L3MBTL1 (0.67) | L3MBTL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL31295414 | 0.81 | CYP1A2 (0.65) | L3MBTL1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL28542694 | 0.81 | GAA (0.58) | L3MBTL1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701635-A1 | 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS | Universitat De Barcelona (ES) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024223907-A1 | 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS | UNIVERSITAT DE BARCELONA (ES) | 2024-10-31 | — | — | WO | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| WO-2006136008-A1 | SALICYLIC ACID HYDRAZONES AS INHIBITORS OF THE ERK MAPKINASE PATHWAY AND FOR THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | L3MBTL1 632/4885MEN1 3370/4885KMT2A 360/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | L3MBTL1 660/4885MEN1 3278/4885KMT2A 348/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | L3MBTL1 659/4885MEN1 3280/4885KMT2A 355/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | L3MBTL1 443/4885MEN1 3835/4885KMT2A 420/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | L3MBTL1 656/4885MEN1 3330/4885KMT2A 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.